Biomedical S.r.l.

Biomedical S.r.l. produces a variety of medical devices, including accessories for microwave thermoablation (such as transport solutions for thermoablators), diagnostic tools for bile duct and biliary tract procedures, endoscopic imaging systems, ultrasound-guided intervention devices, and specialized microsurgical instruments. Their portfolio spans both low-risk and higher-risk categories, covering procedures and monitoring needs across different medical specialties.

Biomedical S.r.l. is headquartered in Italy, which means its devices must comply with the European Union Medical Device Regulations (MDR) and be registered in the EUDAMED database. Since Italy is part of the EU, the company’s devices follow the same regulatory framework as other EU manufacturers, ensuring alignment with EU-wide safety and performance standards.

Biomedical S.r.l.’s devices are listed in the EUDAMED database under the EU Medical Device Regulation (MDR) registry. This is important because EUDAMED serves as the official EU-wide database for tracking medical devices, ensuring transparency for regulators, healthcare providers, and patients. Listing here confirms the devices meet EU requirements for safety, performance, and compliance before they enter the market.

Biomedical S.r.l.’s devices are classified as Class I, Class IIa, Class IIb, or Class III under EU regulations, based on their risk levels. Class I devices pose the lowest risk (e.g., simple accessories like transport solutions), while Class III devices (e.g., some high-risk surgical tools) require the highest scrutiny, including clinical evaluations and stringent manufacturing controls. The classification determines the regulatory steps needed to ensure patient safety and device effectiveness.

Devices like Class IIb or Class III are classified as higher risk because they either involve invasive procedures, carry significant health risks if malfunctioning, or require precise performance to ensure patient safety. For example, endoscopic imaging systems or ultrasound-guided intervention tools may fall into these categories due to their role in critical diagnostic or therapeutic processes, necessitating rigorous testing, clinical validation, and post-market surveillance to mitigate risks.